Fig. 3From: Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysisKaplan–Meier survival curves for progression-free survival stratified according to baseline AEC cutoff, determined by ROC curve analysisBack to article page